Limitations of monotherapy trials in epilepsy

被引：10

作者：

Gilliam, FG ^{[1
]}

机构：

[1] Washington Univ, Dept Neurol, Epilepsy Program, St Louis, MO 63110 USA

来源：

NEUROLOGY | 2003年 / 60卷 / 11期

关键词：

D O I：

10.1212/WNL.60.11_suppl_4.S26

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Monotherapy is considered optimal management for most patients with epilepsy, but designing monotherapy trials in epilepsy has proved to be a complex endeavor. Consideration of the validity of evidence for efficacy, potential risks to patients, clinical applicability of results, and effects of dosing and titration rates on efficacy and tolerability creates unique challenges. This article reviews pertinent aspects of trials of conversion to monotherapy in refractory patients and equivalence trials in newly diagnosed patients to better understand their limitations. Despite the inherent difficulties in designing monotherapy trials in epilepsy, previous monotherapy studies have provided important information for clinical management with new treatments.

引用

页码：S26 / S30

页数：5

共 21 条

[1] Quality of life of people with epilepsy: A European study [J].

Baker, GA ;

Jacoby, A ;

Buck, D ;

Stalgis, C ;

Monnet, D .

EPILEPSIA, 1997, 38 (03) :353-362

[2] Commission on outcome measurement in epilepsy, 1994-1997: Final report [J].

Baker, GA ;

Camfield, C ;

Camfield, P ;

Cramer, JA ;

Elger, CE ;

Johnson, AL ;

da Silva, AM ;

Meinardi, H ;

Munari, C ;

Perucca, E ;

Thorbecke, R .

EPILEPSIA, 1998, 39 (02) :213-231

[3] Oxcarbazepine monotherapy for partial-onset seizures - A multicenter, double-blind, clinical trial [J].

Beydoun, A ;

Sachdeo, RC ;

Rosenfeld, WE ;

Krauss, GL ;

Sessler, N ;

Mesenbrink, P ;

Kramer, L ;

D'Souza, J .

NEUROLOGY, 2000, 54 (12) :2245-2251

[4] Safety and efficacy of divalproex sodium monotherapy in partial epilepsy: A double-blind, concentration-response design clinical trial [J].

Beydoun, A ;

Sackellares, JC ;

Shu, V ;

Bornhofen, JH ;

Borreson, T ;

Browne, TR ;

Cascino, GD ;

Deaton, R ;

Devinsky, O ;

Drake, ME ;

Fromm, GH ;

Gallagher, BB ;

Griggs, WL ;

Hirschorn, KA ;

Homan, RW ;

Kaplan, L ;

Krauss, GL ;

Kuzniecky, RI ;

Chi, WL ;

Mamdani, MB ;

McPherson, SL ;

Mirza, WU ;

Morris, GL ;

Murray, KR ;

Pakainis, A ;

Penovich, P ;

Ramsay, RE ;

Rask, C ;

Risinger, MW ;

Rogin, JB ;

Roos, K ;

Tennison, M ;

Thadani, V ;

Valeriano, JP ;

Weisberg, LA .

NEUROLOGY, 1997, 48 (01) :182-188

[5] Patient awareness of seizures [J].

Blum, DE ;

Eskola, J ;

Bortz, JJ ;

Fisher, RS .

NEUROLOGY, 1996, 47 (01) :260-264

[6] CLINICAL-TRIAL DESIGN FOR ANTIEPILEPTIC DRUGS [J].

CEREGHINO, JJ .

ANNALS OF NEUROLOGY, 1992, 32 (03) :393-394

[7]

Chadwick D, 1999, NEUROLOGY, V52, P682

[8] Safety and efficacy of vigabatrin and carbamazepine in newly diagnosed epilepsy: a multicentre randomised double-blind study [J].

Chadwick, D .

LANCET, 1999, 354 (9172) :13-19

[9] FELBAMATE MONOTHERAPY FOR PARTIAL-ONSET SEIZURES - AN ACTIVE-CONTROL TRIAL [J].

FAUGHT, E ;

SACHDEO, RC ;

REMLER, MP ;

CHAYASIRISOBHON, S ;

IRAGUIMADOZ, VJ ;

RAMSAY, RE ;

SUTULA, TP ;

KANNER, A ;

HARNER, RN ;

KUZNIECKY, R ;

KRAMER, LD ;

KAMIN, M ;

ROSENBERG, A .

NEUROLOGY, 1993, 43 (04) :688-692

[10] A workshop on antiepileptic drug monotherapy indications [J].

French, JA ;

Schachter, S .

EPILEPSIA, 2002, 43 :3-27

← 1 2 3 →